Challenges for cancer vaccine development

Advanced Drug Delivery Reviews

Volumn 58, Issue 8, 2006, Pages 902-915

  Tabi, Z ^a   Man, S ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Immune evasion; Immunotherapy; Tumour vaccines

Indexed keywords

BIOMEDICAL ENGINEERING; CONTROLLED DRUG DELIVERY; IMMUNOLOGY; TUMORS;

IMMUNE EVASION; IMMUNOTHERAPY; TUMOR VACCINES;

VACCINES;

BLP 25; CANCER VACCINE; CANVAXIN; GV 1001; GVAX; INSEGIA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPHAGE; ONYVAX; ONYVAX P; PANVAC; PROVENGE; STIMUVAX; TG 4010; TROVAX; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; AUTOIMMUNITY; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DOWN REGULATION; EFFECTOR CELL; FATIGUE; FLU LIKE SYNDROME; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE IRRITATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROMA; VACCINATION REACTION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS;

EID: 33750716845     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.05.004     Document Type: Review

References (115)

1. IARC. World Cancer Report, (WHO), 2003.
2. Rosenberg S., Yang J., and Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10 (2004) 909-915
3. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., and Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
4. Traversari C., van der Bruggen P., Luescher I., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., and Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176 (1992) 1453-1457
5. Maeurer M., Martin D., Elder E., Storkus W., and Lotze M. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Clin. Cancer Res. 2 (1996) 87-95
6. Hofmann S., Glückmann M., Kausche S., Schmidt A., Corvey C., Lichtenfels R., Huber C., Albrecht C., Karas M., and Herr W. Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol. Cell Proteomics 4 (2005) 1888-1897
7. Zhang Y., Geng Y., Zhou L., Lai B., Si L., and Wang Y. Identification of proteins of human colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. World J. Gastroenterol. 11 (2005) 4679-4684
8. Shoshan S., and Admon A. Proteomics in cancer vaccine development. Expert Rev. Proteomics 2 (2005) 229-241
9. Schwartz S., Weil R., Thompson R., Shyr Y., Moore J., Toms S., Johnson M., and Caprioli R. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. 65 (2005) 7674-7681
10. Britten R., Hardy C., Vlahou A., Gregory B., Giri P., and Drake R. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. Oncol. Rep. 14 (2005) 1323-1330
11. Lancashire L., Schmid O., Shah H., and Ball G. Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks, cluster analysis and principal components analysis. Bioinformatics 21 (2005) 2191-2199
12. Chen Y., Zheng S., Yu J., and Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res. 10 (2004) 8380-8385
13. Türeci O., Sahin U., Schobert I., Koslowski M., Scmitt H., Schild H., Stenner F., Seitz G., Rammensee H., and Pfreundschuh M. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56 (1996) 4766-4772
14. Miles A., Matharoo-Ball B., Li G., Ahmad M., and Rees R. The identification of human tumour antigens: current status and future developments. Cancer Immunol. Immunother. 55 (2006) 996-1003
15. Kononen J., Bubendorf L., Kallioniemi A., Bärlund M., Schraml P., Leighton S., Torhorst J., Mihatsch M., Sauter G., and Kallioniemi O. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4 (1998) 844-847
16. Dhanasekaran S., Barrette T., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K., Rubin M., and Chinnaiyan A. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
17. Zhang L., Zhou W., Velculescu V., Kern S., Hruban R., Hamilton S., Vogelstein B., and Kinzler K. Gene expression profiles in normal and cancer cells. Science 276 (1997) 1268-1272
18. Pinkel D., and Albertson D. Array comparative genomic hybridization and its applications in cancer. Nat. Genet. 37 (2005) S11-S17 Suppl.
19. Brenner S., Johnson M., Bridgham J., Golda G., Lloyd D., Johnson D., Luo S., McCurdy S., Foy M., Ewan M., et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat. Biotechnol. 18 (2000) 630-634
20. Bucca G., Carruba G., Saetta A., Muti P., Castagnetta L., and Smith C. Gene expression profiling of human cancers. Ann. N. Y. Acad. Sci. 1028 (2004) 28-37
21. Elfilali A., Lair S., Verbeke C., La Rosa P., Radvanyi F., and Barillot E. ITTACA: a new database for integrated tumor transcriptome array and clinical data analysis. Nucleic Acids Res. 34 (2006) D613-D616
22. Boon T., and van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183 (1996) 725-729
23. Neumann F., Wagner C., Kubuschok B., Stevanovic S., Rammensee H., and Pfreundschuh M. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol. Immunother. 53 (2004) 589-599
24. Nishikawa H., Kato T., Tanida K., Hiasa A., Tawara I., Ikeda H., Ikarashi Y., Wakasugi H., Kronenberg M., Nakayama T., et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10902-10906
25. Nishikawa H., Kato T., Tawara I., Ikeda H., Kuribayashi K., Allen P., Schreiber R., Old L., and Shiku H. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J. Immunol. 175 (2005) 4433-4440
26. Chen Y., Scanlan M., Sahin U., Türeci O., Gure A., Tsang S., Williamson B., Stockert E., Pfreundschuh M., and Old L. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 1914-1918
27. Valmori D., Dutoit V., Liénard D., Rimoldi D., Pittet M., Champagne P., Ellefsen K., Sahin U., Speiser D., Lejeune F., et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60 (2000) 4499-4506
28. Chen J., Dunbar P., Gileadi U., Jäger E., Gnjatic S., Nagata Y., Stockert E., Panicali D., Chen Y., Knuth A., et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165 (2000) 948-955
29. Nicholaou T., Ebert L., Davis I., Robson N., Klein O., Maraskovsky E., Chen W., and Cebon J. Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1. Immunol. Cell Biol. 84 (2006) 303-317
30. *04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27 (2004) 472-477
31. Davis I., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., Chen Q., Dimopoulos N., Luke T., Murphy R., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10697-10702
32. Barrow C., Browning J., MacGregor D., Davis I., Sturrock S., Jungbluth A., and Cebon J. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12 (2006) 764-771
33. Menon A., Fleuren G., Alphenaar E., Jonges L., Janssen van Rhijn C., Ensink N., Putter H., Tollenaar R., van de Velde C., and Kuppen P. A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer. Cancer Immunol. Immunother. 52 (2003) 121-126
34. Singh S., Ross S., Acena M., Rowley D., and Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175 (1992) 139-146
35. Yu P., Rowley D., Fu Y., and Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr. Opin. Immunol. 18 (2006) 226-231
36. Hofmeister V., Vetter C., Schrama D., Bröcker E., and Becker J. Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunol. Immunother. 55 (2006) 481-494
37. Hanson H., Donermeyer D., Ikeda H., White J., Shankaran V., Old L., Shiku H., Schreiber R., and Allen P. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13 (2000) 265-276
38. Yang F., Tuxhorn J., Ressler S., McAlhany S., Dang T., and Rowley D. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 65 (2005) 8887-8895
39. Lee J., Fassnacht M., Nair S., Boczkowski D., and Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 65 (2005) 11156-11163
40. Hofmeister V., Vetter C., Schrama D., Brocker E.B., and Becker J.C. Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunol. Immunother. 55 (2006) 481-494
41. El Hilali N., Rubio N., and Blanco J. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase. Clin. Cancer Res. 11 (2005) 1253-1258
42. Vosseler S., Mirancea N., Bohlen P., Mueller M., and Fusenig N. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 65 (2005) 1294-1305
43. Spiotto M., Rowley D., and Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10 (2004) 294-298
44. Tuxhorn J., McAlhany S., Yang F., Dang T., and Rowley D. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 62 (2002) 6021-6025
45. Sugimoto T., Takiguchi Y., Kurosu K., Kasahara Y., Tanabe N., Tatsumi K., Hiroshima K., Minamihisamatsu M., Miyamoto T., and Kuriyama T. Growth factor-mediated interaction between tumor cells and stromal fibroblasts in an experimental model of human small-cell lung cancer. Oncol. Rep. 14 (2005) 823-830
46. Zhou H., Luo Y., Mizutani M., Mizutani N., Reisfeld R., and Xiang R. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 106 (2005) 2026-2032
47. Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
48. Strasly M., Cavallo F., Geuna M., Mitola S., Colombo M., Forni G., and Bussolino F. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 166 (2001) 3890-3899
49. Blohm U., Potthoff D., van der Kogel A., and Pircher H. Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur. J. Immunol. 36 (2006) 468-477
50. Terabe M., Matsui S., Park J., Mamura M., Noben-Trauth N., Donaldson D., Chen W., Wahl S., Ledbetter S., Pratt B., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198 (2003) 1741-1752
51. Makarenkova V., Bansal V., Matta B., Perez L., and Ochoa J. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176 (2006) 2085-2094
52. Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., Zanovello P., and Bronte V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53 (2004) 64-72
53. Huang B., Pan P., Li Q., Sato A., Levy D., Bromberg J., Divino C., and Chen S. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66 (2006) 1123-1131
54. Sinha P., Clements V., and Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65 (2005) 11743-11751
55. Serafini P., Borrello I., and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16 (2006) 53-65
56. Yang L., DeBusk L., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L., Carbone D., and Lin P. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cells 6 (2004) 409-421
57. Sinha P., Clements V., and Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174 (2005) 636-645
58. Suzuki E., Kapoor V., Jassar A., Kaiser L., and Albelda S. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11 (2005) 6713-6721
59. Rodriguez P., Quiceno D., Zabaleta J., Ortiz B., Zea A., Piazuelo M., Delgado A., Correa P., Brayer J., Sotomayor E., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64 (2004) 5839-5849
60. Rapoport A., Stadtmauer E., Aqui N., Badros A., Cotte J., Chrisley L., Veloso E., Zheng Z., Westphal S., Mair R., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11 (2005) 1230-1237
61. Gattinoni L., Powell D., Rosenberg S., and Restifo N. Adoptive immunotherapy for cancer: building on success. Nat. Rev., Immunol. 6 (2006) 383-393
62. Hu H., Poehlein C., Urba W., and Fox B. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 62 (2002) 3914-3919
63. Gattinoni L., Finkelstein S., Klebanoff C., Antony P., Palmer D., Spiess P., Hwang L., Yu Z., Wrzesinski C., Heimann D., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202 (2005) 907-912
64. Wang L., Li R., Yang G., Lim M., O'Hara A., Chu Y., Fox B., Restifo N., Urba W., and Hu H. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 65 (2005) 10569-10577
65. Jager E., Ringhoffer M., Karbach J., Arand M., Oesch F., and Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66 (1996) 470-476
66. Maeurer M.J., Gollin S.M., Martin D., Swaney W., Bryant J., Castelli C., Robbins P., Parmiani G., Storkus W.J., and Lotze M.T. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 98 (1996) 1633-1641
67. Jager E., Ringhoffer M., Altmannsberger M., Arand M., Karbach J., Jager D., Oesch F., and Knuth A. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71 (1997) 142-147
68. Gottschalk S., Ng C.Y., Perez M., Smith C.A., Sample C., Brenner M.K., Heslop H.E., and Rooney C.M. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97 (2001) 835-843
69. Lurquin C., Lethe B., De Plaen E., Corbiere V., Theate I., van Baren N., Coulie P.G., and Boon T. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201 (2005) 249-257
70. Yewdell J.W. The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol. Rev. 207 (2005) 8-18
71. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21 (2000) 455-464
72. Maeurer M.J., Gollin S.M., Storkus W.J., Swaney W., Karbach J., Martin D., Castelli C., Salter R., Knuth A., and Lotze M.T. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin. Cancer Res. 2 (1996) 641-652
73. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M., and Stern P.L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18 (1997) 89-95
74. Koopman L.A., van Der Slik A.R., Giphart M.J., and Fleuren G.J. Human leukocyte antigen class I gene mutations in cervical cancer. J. Natl. Cancer Inst. 91 (1999) 1669-1677
75. Cabrera C.M., Jimenez P., Cabrera T., Esparza C., Ruiz-Cabello F., and Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 61 (2003) 211-219
76. Storkus W.J., Howell D.N., Salter R.D., Dawson J.R., and Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol. 138 (1987) 1657-1659
77. Yokoyama W.M., and Plougastel B.F. Immune functions encoded by the natural killer gene complex. Nat. Rev., Immunol. 3 (2003) 304-316
78. Wu J.D., Higgins L.M., Steinle A., Cosman D., Haugk K., and Plymate S.R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114 (2004) 560-568
79. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mule J.J., Rosenberg S.A., and Bennink J.R. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177 (1993) 265-272
80. Seliger B., Schreiber K., Delp K., Meissner M., Hammers S., Reichert T., Pawlischko K., Tampe R., and Huber C. Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 57 (2001) 39-45
81. Evans M., Borysiewicz L.K., Evans A.S., Rowe M., Jones M., Gileadi U., Cerundolo V., and Man S. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 167 (2001) 5420-5428
82. Glew S.S., Duggan-Keen M., Cabrera T., and Stern P.L. HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res. 52 (1992) 4009-4016
83. Daniel D., Chiu C., Giraudo E., Inoue M., Mizzen L.A., Chu N.R., and Hanahan D. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 65 (2005) 2018-2025
84. Corthay A., Skovseth D.K., Lundin K.U., Rosjo E., Omholt H., Hofgaard P.O., Haraldsen G., and Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22 (2005) 371-383
85. van Hall T., Wolpert E.Z., van Veelen P., Laban S., van der Veer M., Roseboom M., Bres S., Grufman P., de Ru A., and Meiring H. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 12 (2006) 417-424
86. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., Knutson K.L., and Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20 (2002) 2624-2632
87. Marchand M., van Baren N., Weynants P., Brichard V., Dréno B., Tessier M., Rankin E., Parmiani G., Arienti F., Humblet Y., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80 (1999) 219-230
88. Michael A., Ball G., Quatan N., Wushishi F., Russell N., Whelan J., Chakraborty P., Leader D., Whelan M., and Pandha H. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. 11 (2005) 4469-4478
89. Hopkins M. Can super-antibody drugs be tamed?. Nature 440 (2006) 855-856
90. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W.G., Westmoreland D., Evans A.S., Adams M., Stacey S.N., Boursnell M.E.G., et al. A recombinant vaccinia virus encoding human papillomavirus type 16 and type 18, e6 and e7 proteins as immunotherapy for cervical cancer. Lancet 347 (1996) 1523-1527
91. Soiffer R., Hodi F.S., Haluska F., Jung K., Gillessen S., Singer S., Tanabe K., Duda R., Mentzer S., Jaklitsch M., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21 (2003) 3343-3350
92. Carr A., Rodriguez E., Arango Mdel C., Camacho R., Osorio M., Gabri M., Carrillo G., Valdes Z., Bebelagua Y., Perez R., and Fernandez L.E. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 21 (2003) 1015-1021
93. Update: Vaccine Side Effects, Adverse Reactions, Contraindications, and Precautions Recommendations of the Advisory Committee on Immunization Practices (ACIP).http://www.cdcgov.com/mmwr/preview/mmwr.html/00046738.htm, (1996).
94. Smith C.L., Dunbar P.R., Mirza F., Palmowski M.J., Shepherd D., Gilbert S.C., Coulie P., Schneider J., Hoffman E., Hawkins R., et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113 (2005) 259-266
95. McMichael A., and O'Callaghan C. A new look at T cells. J. Exp. Med. 187 (1998) 1367-1371
96. Overwijk W.W., Lee D.S., Surman D.R., Irvine K.R., Touloukian C.E., Chan C.C., Carroll M.W., Moss B., Rosenberg S.A., and Restifo N.P. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2982-2987
97. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8372-8377
98. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
99. Steyer R. CancerVax Ends Canvaxin Research (2005). http://www.thestreet.com/stocks/robertsteyer/10245499.html
100. Offringa R. Tumour immunology exploitation of the weapon of immune destruction for cancer therapy: taking aim before firing. Curr. Opin. Immunol. 17 (2005) 159-162
101. Friede M., and Aguado M.T. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Adv. Drug Deliv. Rev. 57 (2005) 325-331
102. Coleman S., Clayton A., Mason M.D., Jasani B., Adams M., and Tabi Z. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res. 65 (2005) 7000-7006
103. Chen J.L., Stewart-Jones G., Bossi G., Lissin N.M., Wooldridge L., Choi E.M., Held G., Dunbar P.R., Esnouf R.M., Sami M., et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201 (2005) 1243-1255
104. Silk J.D., Hermans I.F., Gileadi U., Chong T.W., Shepherd D., Salio M., Mathew B., Schmidt R.R., Lunt S.J., Williams K.J., et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J. Clin. Invest. 114 (2004) 1800-1811
105. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
106. Greer, M. Dendreon's Second Randomized Phase 3 D9902A Trial of Provenge Extends Survival in Patients with Advanced Prostate Cancer. http://investordendreoncom/ReleaseDetailcfm?ReleaseID=178106 and Header=News, (2005).
107. Oxford Biomedica presents encouraging final phase II results with Trovax® in colorectal cancer at the International Colorectal Cancer Congress. http://www.oxfordbiomedica.co.uk/news/2005-ob-31.htm, (2005).
108. TG 4010 (MVA-MUC1-IL2). http://www.mpip.org/news/5_13_99_1.html, (2005).
109. Therion Reports Results of Phase 3 PANVAC-VF Trial. http://www.therion.com/news/pressSingle.asp?id=547, (2006).
110. Biomira announces final phase 2b survival results of Stimuvax® (formerly known as BLP25 Liposome Vaccine) trial in patients with non-small cell lung cancer-results confirm median survival of 30.6 months in stage IIIB patients on vaccine versus 13.3 months in control patients. http://www.biomira.com/news/detailNewsRelease/248/, (2006).
111. Phase 3 Trial of InsegiaTM in Pancreatic Cancer Does Not Meet Primary Endpoint: Survival Advantage Seen in Patients who Achieve Antibody Response. http://www.aphton.com/news_main.asp?PR_ID=109, (2005).
112. GVax immunotherapy for prostate cancer. http://www.cellgenesys.com/clinicaltrials-prostate-cancers.html, (2005).
113. Cell Genesys to Present Data From Two GVAX(R) Cancer Immunotherapy Clinical Trials at 2006 ASCO Annual Meeting. http://phx.corporate-ir.net/phoenixz.html?c=98399 and p=irol-newsArticle and ID=830350 and highlight=, (2006).
114. Antigenics Reports Phase 3 Results for Oncophage in Kidney Cancer. http://www.antigenics.com/news/2006/0324p.html, (2006).
115. Pharmexa Goes to Phase III. http://www.pharmalive.com/news/index.cfm?articleid=334653 and search=1, (2006).